The US dollar rallied consequently since the beginning of the US-Iran conflict, supported by the rise in oil prices.

Q4 2025 earnings call recap: 2026 revenue/EBITDA guidance, AI-driven cost cuts, ARR/retention trends, and new markets—read now.

Q4 2025 Earnings Call March 19, 2026 5:00 PM EDTCompany ParticipantsYojin Yoon - Vice President of OperationsJoshua ...

Peter Kang, Senior VP, highlighted that "the fourth quarter capped a pivotal year for Snail and the ARK franchise," noting milestones such as the launch of ARK: Lost Colony DLC and the introduction of ...

He stated, "I have made the decision to retire as CEO of electroCore effective April 1, 2026... With that foundation now in place, the board and I believe this is the right time to begin a leadership ...

Caleres, Inc. reported weak Q4 '25 results, with flat organic sales and significant margin deleverage despite headline growth from the Stuart Weitzman acquisition. I view CAL stock as fairly valued at ...

US crude oil eased after Israel Prime Minister Netanyahu said Iran no longer has the capacity to enrich uranium or make ballistic missiles and Israel will help reopen the Strait of Hormuz.

KB Home faces persistent headwinds from affordability challenges, weak consumer sentiment, and higher mortgage rates, particularly impacting its first-time buyer focus. Q1 earnings expectations are ...

Globus Medical is rated a buy, driven by robust earnings growth, margin recovery, and strong management guidance following a transformative year. GMED’s acquisition of Nevro accelerated revenue and ...

Blue Owl stock is gaining Wall Street's attention. Read what investors should know about the challenges facing this company.

Q4 2025 earnings call recap: subscription growth, AI product launches, 77% gross margin, and 2026 ARR/EBITDA targets—read now.

Good day, and thank you for standing by. Welcome to the Taysha Gene Therapies Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is ...